Effect of docosahexaenoic acid on lipoprotein subclasses in hyperlipidemic children (the EARLY study)

Am J Cardiol. 2005 Apr 1;95(7):869-71. doi: 10.1016/j.amjcard.2004.12.014.

Abstract

To test the hypothesis that a dietary omega-3 fatty acid, docosahexaenoic acid, improves the lipoprotein subclass profile of children who have hyperlipidemia, we conducted a randomized, double-blind, placebo-controlled study. Children who had hyperlipidemia (n = 20) were stabilized on a low-fat diet for 6 weeks and then randomized to receive 1.2 g/day of docosahexaenoic acid for 6 weeks or placebo. Supplementation with docosahexaenoic acid significantly increased low-density lipoprotein subclass 1 and high-density lipoprotein subclass 2 (large and buoyant; less atherogenic particles) by 91% and 14%, respectively, compared with the placebo phase. Low-density lipoprotein subclass 3 (small and dense; more atherogenic particles) decreased by 48%.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Child
  • Cross-Over Studies
  • Dietary Supplements
  • Docosahexaenoic Acids / pharmacology
  • Docosahexaenoic Acids / therapeutic use*
  • Double-Blind Method
  • Female
  • Humans
  • Hyperlipidemia, Familial Combined / drug therapy*
  • Lipoproteins / classification
  • Lipoproteins / drug effects
  • Male

Substances

  • Lipoproteins
  • Docosahexaenoic Acids